CS Venkatakrishnan, the CEO of Barclays, will be undergoing treatment for non-Hodgkin lymphoma for the next 12-16 weeks, The Financial Times’ Oliver Ralph reports. In a letter to staff, Venkatakrishnan wrote: "The doctors have advised that my prognosis is excellent, and my condition is curable with their prescribed regimen." He also said: "During this period, the company will run normally, and I will continue to be actively engaged in managing it. However, I will have to work from home for some periods and not be able to travel." Reference Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCS: